Search - tctmd.com

Displaying 121 - 140 of 206

Sort: Relevancy | Date

News Conference News AHA 2019

EVAPORATE Hints at Slowed Plaque Progression With Icosapent Ethyl

Todd Neale

November 18, 2019

Presentation AHA 2019

Effect of Icosapent Ethyl on Progression of Coronary Atherosclerosis in Patients With Elevated Triglycerides on Statin Therapy: The EVAPORATE Study

Presenter: Matthew Budoff

November 18, 2019

News Conference News AHA 2019

Inclisiran Slashes LDL in ASCVD Patients: ORION-10

Yael L. Maxwell

November 16, 2019

COLCOT Renews Hope for Anti-inflammatory Secondary Prevention

News Conference News AHA 2019

COLCOT Renews Hope for Anti-inflammatory in Secondary Prevention: Colchicine

Caitlin E. Cox

November 16, 2019

News Daily News

FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl

Michael O'Riordan

November 14, 2019

News Daily News

Vasospasm, Microvascular Dysfunction Tied to MACE in Nonobstructive CAD

Michael O'Riordan

November 05, 2019

News Daily News

Bleeding on Low-Dose Antithrombotic Therapy a ‘Red Flag’ for New Cancers

Yael L. Maxwell

September 20, 2019

News Conference News ESC 2019

Updated EAS/ESC Dyslipidemia Guidelines Lower LDL Targets, Broaden Risk Categories

Yael L. Maxwell

September 06, 2019

News Conference News ESC 2019

Young MI Patients’ Ischemic Risk Extends at Least Two Decades

Caitlin E. Cox

September 06, 2019

News Daily News

Statin Discontinuation in the Elderly Linked to More CV Events

Yael L. Maxwell

August 01, 2019

News Daily News

Nonobstructive CAD on Cardiac CTA a Golden Opportunity to Boost Statin Prescribing

Michael O'Riordan

July 22, 2019

News Conference News SCCT 2019

Imaging, Genes, Wearables: Some Predictions for the Future of Preventive Cardiology

Yael L. Maxwell

July 15, 2019

News Daily News

High Levels of Lp(a) Linked to Increased Ischemic Stroke Risk

Michael O'Riordan

July 01, 2019

News Conference News EAS 2019

Should Lp(a) Be Measured and Treated? Two Experts Hash Out Its Current Role

Michael O'Riordan

June 07, 2019

News Conference News EAS 2019

Absence of FH Diagnosis Linked to Increased Risk of Premature Mortality

Michael O'Riordan

June 05, 2019

News Conference News EAS 2019

Inclisiran Safe and Effective in Patients With Impaired Renal Function: ORION

Michael O'Riordan

June 04, 2019

News Conference News EAS 2019

FH Patients Derive Biggest Absolute Benefit From Statin Therapy: 4S Analysis

Michael O'Riordan

June 03, 2019

News Conference News EAS 2019

CHD Mortality Significantly Elevated in Patients With Severe FH

Michael O'Riordan

May 29, 2019

News Daily News

Higher Risk of Intracranial Hemorrhage With Aspirin in Primary Prevention

Michael O'Riordan

May 20, 2019

News Daily News

Elevations in hs-cTnI Linked to Higher Risk of CVD, Particularly Heart Failure

Michael O'Riordan

May 06, 2019

Advertisement

EVAPORATE Hints at Slowed Plaque Progression With Icosapent Ethyl

Effect of Icosapent Ethyl on Progression of Coronary Atherosclerosis in Patients With Elevated Triglycerides on Statin Therapy: The EVAPORATE Study

Inclisiran Slashes LDL in ASCVD Patients: ORION-10

COLCOT Renews Hope for Anti-inflammatory in Secondary Prevention: Colchicine

FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl

Vasospasm, Microvascular Dysfunction Tied to MACE in Nonobstructive CAD

Bleeding on Low-Dose Antithrombotic Therapy a ‘Red Flag’ for New Cancers

Updated EAS/ESC Dyslipidemia Guidelines Lower LDL Targets, Broaden Risk Categories

Young MI Patients’ Ischemic Risk Extends at Least Two Decades

Statin Discontinuation in the Elderly Linked to More CV Events

Nonobstructive CAD on Cardiac CTA a Golden Opportunity to Boost Statin Prescribing

Imaging, Genes, Wearables: Some Predictions for the Future of Preventive Cardiology

High Levels of Lp(a) Linked to Increased Ischemic Stroke Risk

Should Lp(a) Be Measured and Treated? Two Experts Hash Out Its Current Role

Absence of FH Diagnosis Linked to Increased Risk of Premature Mortality

Inclisiran Safe and Effective in Patients With Impaired Renal Function: ORION

FH Patients Derive Biggest Absolute Benefit From Statin Therapy: 4S Analysis

CHD Mortality Significantly Elevated in Patients With Severe FH

Higher Risk of Intracranial Hemorrhage With Aspirin in Primary Prevention

Elevations in hs-cTnI Linked to Higher Risk of CVD, Particularly Heart Failure

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content